Skip to main content

ARROWHEAD PHARMACEUTICALS, INC.

For the period ended Sep 30, 2025. Filed Nov 25, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Nov 25, 2025

ARWR$49.24-15.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 25, 2025

ARROWHEAD PHARMACEUTICALS, INC.
By:/s/ Christopher Anzalone
Christopher Anzalone
Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Anzalone and Daniel Apel, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign in any and all capacities (including, without limitation, the capacities listed below), this Annual Report on Form 10-K, any and all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and anything necessary to be done to enable the registrant to comply with the provisions of the Securities Exchange Act and all the requirements of the Securities and Exchange Commission, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute, or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

SignatureTitleDate
/s/ Christopher AnzaloneChief Executive Officer, President and Director, Chairman of the Board of Directors (Principal Executive Officer)November 25, 2025
Christopher Anzalone
/s/ Daniel ApelChief Financial Officer (Principal Financial and Accounting Officer)November 25, 2025
Daniel Apel
/s/ Mauro FerrariDirectorNovember 25, 2025
Mauro Ferrari
/s/ Douglass IngramDirectorNovember 25, 2025
Douglass Ingram
/s/ Hongbo LuDirectorNovember 25, 2025
Hongbo Lu
/s/ Adeoye OlukotunDirectorNovember 25, 2025
Adeoye Olukotun
/s/ Michael S. PerryDirectorNovember 25, 2025
Michael S. Perry
/s/ Victoria VakienerDirectorNovember 25, 2025
Victoria Vakiener
/s/ William WaddillDirectorNovember 25, 2025
William Waddill
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.